Millendo Therapeutics (NASDAQ:MLND) Shares Up 10.4%

Millendo Therapeutics Inc (NASDAQ:MLND) traded up 10.4% on Thursday . The stock traded as high as $1.92 and last traded at $1.80. 3,857,446 shares changed hands during mid-day trading, an increase of 364% from the average session volume of 831,054 shares. The stock had previously closed at $1.63.

MLND has been the topic of several recent analyst reports. Wedbush restated a “hold” rating and set a $3.00 price objective on shares of Millendo Therapeutics in a research note on Wednesday, August 12th. SVB Leerink reiterated an “outperform” rating and issued a $5.00 price objective on shares of Millendo Therapeutics in a research note on Sunday, June 14th. Zacks Investment Research downgraded Millendo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 14th. Roth Capital reaffirmed a “buy” rating and set a $6.00 target price on shares of Millendo Therapeutics in a research report on Sunday, June 14th. Finally, ValuEngine downgraded shares of Millendo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, August 3rd. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Millendo Therapeutics has a consensus rating of “Buy” and an average price target of $3.96.

The business has a 50 day moving average of $1.69 and a 200-day moving average of $2.29. The company has a market capitalization of $30.97 million, a P/E ratio of -0.55 and a beta of 1.36. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.36 and a current ratio of 5.36.

Millendo Therapeutics (NASDAQ:MLND) last posted its earnings results on Monday, August 10th. The company reported ($0.56) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.01). As a group, equities analysts forecast that Millendo Therapeutics Inc will post -2.13 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in Millendo Therapeutics by 31.4% in the 1st quarter. JPMorgan Chase & Co. now owns 34,986 shares of the company’s stock worth $185,000 after purchasing an additional 8,362 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Millendo Therapeutics by 47.0% during the 1st quarter. Bank of New York Mellon Corp now owns 28,411 shares of the company’s stock valued at $150,000 after buying an additional 9,083 shares in the last quarter. State Street Corp lifted its holdings in shares of Millendo Therapeutics by 7.1% during the 1st quarter. State Street Corp now owns 178,642 shares of the company’s stock worth $943,000 after acquiring an additional 11,906 shares during the last quarter. Nuveen Asset Management LLC grew its position in Millendo Therapeutics by 90.9% in the first quarter. Nuveen Asset Management LLC now owns 28,380 shares of the company’s stock worth $149,000 after acquiring an additional 13,515 shares in the last quarter. Finally, Two Sigma Advisers LP bought a new position in Millendo Therapeutics in the second quarter valued at $25,000. Institutional investors own 44.41% of the company’s stock.

About Millendo Therapeutics (NASDAQ:MLND)

Millendo Therapeutics, Inc, a late-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; and nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia.

Read More: What is Compound Annual Growth Rate (CAGR)?

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.